A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C (Insulin 287) at Steady State Conditions in Subjects With Type 1 Diabetes
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Insulin icodec (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 06 Oct 2023 Primary endpoint has not been met, (AUCI287,,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state), as per Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 06 Oct 2023 Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 03 Jul 2020 Status changed from active, no longer recruiting to completed.